These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 25108876)

  • 1. Breakthrough candidaemia caused by phenotypically susceptible Candida spp. in patients with haematological malignancies does not correlate with established interpretive breakpoints.
    Gamaletsou MN; Daikos GL; Walsh TJ; Perlin DS; Ortigosa CJ; Psaroulaki A; Pagoni M; Argyropoulou A; Nepka M; Perivolioti E; Kotsopoulou M; Perloretzou S; Marangos M; Kofteridis D; Grammatikou M; Goukos D; Petrikkos G; Sipsas NV
    Int J Antimicrob Agents; 2014 Sep; 44(3):248-55. PubMed ID: 25108876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective, cohort, multicentre study of candidaemia in hospitalized adult patients with haematological malignancies.
    Gamaletsou MN; Walsh TJ; Zaoutis T; Pagoni M; Kotsopoulou M; Voulgarelis M; Panayiotidis P; Vassilakopoulos T; Angelopoulou MK; Marangos M; Spyridonidis A; Kofteridis D; Pouli A; Sotiropoulos D; Matsouka P; Argyropoulou A; Perloretzou S; Leckerman K; Manaka A; Oikonomopoulos P; Daikos G; Petrikkos G; Sipsas NV
    Clin Microbiol Infect; 2014 Jan; 20(1):O50-7. PubMed ID: 23889746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical characteristics of candidaemia in adults with haematological malignancy, and antimicrobial susceptibilities of the isolates at a medical centre in Taiwan, 2001-2010.
    Chen CY; Huang SY; Tsay W; Yao M; Tang JL; Ko BS; Chou WC; Tien HF; Hsueh PR
    Int J Antimicrob Agents; 2012 Dec; 40(6):533-8. PubMed ID: 23006521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Candidaemia in haematological malignancy patients from a SEIFEM study: Epidemiological patterns according to antifungal prophylaxis.
    Posteraro B; De Carolis E; Criscuolo M; Ballanti S; De Angelis G; Del Principe MI; Delia M; Fracchiolla N; Marchesi F; Nadali G; Picardi M; Piccioni AL; Verga L; Candoni A; Busca A; Sanguinetti M; Pagano L;
    Mycoses; 2020 Sep; 63(9):900-910. PubMed ID: 32531854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Support for the EUCAST and revised CLSI fluconazole clinical breakpoints by Sensititre® YeastOne® for Candida albicans: a prospective observational cohort study.
    van Hal SJ; Chen SC; Sorrell TC; Ellis DH; Slavin M; Marriott DM
    J Antimicrob Chemother; 2014 Aug; 69(8):2210-4. PubMed ID: 24788656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidemiology and outcome of candidaemia in patients with oncological and haematological malignancies: results from a population-based surveillance in Spain.
    Puig-Asensio M; Ruiz-Camps I; Fernández-Ruiz M; Aguado JM; Muñoz P; Valerio M; Delgado-Iribarren A; Merino P; Bereciartua E; Fortún J; Cuenca-Estrella M; Almirante B; ; ;
    Clin Microbiol Infect; 2015 May; 21(5):491.e1-10. PubMed ID: 25703212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Candida species bloodstream infection: epidemiology and outcome in a single institution from 1991 to 2008.
    Ortega M; Marco F; Soriano A; Almela M; Martínez JA; López J; Pitart C; Mensa J
    J Hosp Infect; 2011 Feb; 77(2):157-61. PubMed ID: 21216030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidemiology of candidaemia and antifungal susceptibility patterns in an Italian tertiary-care hospital.
    Bedini A; Venturelli C; Mussini C; Guaraldi G; Codeluppi M; Borghi V; Rumpianesi F; Barchiesi F; Esposito R
    Clin Microbiol Infect; 2006 Jan; 12(1):75-80. PubMed ID: 16460550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death.
    Slavin MA; Sorrell TC; Marriott D; Thursky KA; Nguyen Q; Ellis DH; Morrissey CO; Chen SC;
    J Antimicrob Chemother; 2010 May; 65(5):1042-51. PubMed ID: 20202987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluconazole non-susceptible breakthrough candidemia after prolonged low-dose prophylaxis: a prospective FUNGINOS study.
    Orasch C; Mertz D; Garbino J; van Delden C; Emonet S; Schrenzel J; Zimmerli S; Damonti L; Mühlethaler K; Imhof A; Ruef C; Fehr J; Zbinden R; Boggian K; Bruderer T; Flückiger U; Conen A; Khanna N; Frei R; Bregenzer T; Lamoth F; Erard V; Bochud PY; Calandra T; Bille J; Marchetti O;
    J Infect; 2018 May; 76(5):489-495. PubMed ID: 29378240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Candidaemia with uncommon Candida species: predisposing factors, outcome, antifungal susceptibility, and implications for management.
    Chen SC; Marriott D; Playford EG; Nguyen Q; Ellis D; Meyer W; Sorrell TC; Slavin M;
    Clin Microbiol Infect; 2009 Jul; 15(7):662-9. PubMed ID: 19614718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009).
    Pfaller MA; Messer SA; Moet GJ; Jones RN; Castanheira M
    Int J Antimicrob Agents; 2011 Jul; 38(1):65-9. PubMed ID: 21514797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: data from a nationwide fungaemia surveillance programme.
    Arendrup MC; Dzajic E; Jensen RH; Johansen HK; Kjaeldgaard P; Knudsen JD; Kristensen L; Leitz C; Lemming LE; Nielsen L; Olesen B; Rosenvinge FS; Røder BL; Schønheyder HC
    Clin Microbiol Infect; 2013 Aug; 19(8):E343-53. PubMed ID: 23607326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breakthrough candidemia after the introduction of broad spectrum antifungal agents: A 5-year retrospective study.
    Breda GL; Tuon FF; Meis JF; Herkert PF; Hagen F; de Oliveira LZ; Dias VC; da Cunha CA; Queiroz-Telles F
    Med Mycol; 2018 Jun; 56(4):406-415. PubMed ID: 29420820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness of echinocandins versus fluconazole therapy for the treatment of adult candidaemia due to Candida parapsilosis: a retrospective observational cohort study of the Mycoses Study Group (MSG-12).
    Chiotos K; Vendetti N; Zaoutis TE; Baddley J; Ostrosky-Zeichner L; Pappas P; Fisher BT
    J Antimicrob Chemother; 2016 Dec; 71(12):3536-3539. PubMed ID: 27494929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nosocomial bloodstream infections due to Candida spp. in the USA: species distribution, clinical features and antifungal susceptibilities.
    Wisplinghoff H; Ebbers J; Geurtz L; Stefanik D; Major Y; Edmond MB; Wenzel RP; Seifert H
    Int J Antimicrob Agents; 2014 Jan; 43(1):78-81. PubMed ID: 24182454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Candidemia surveillance in Iowa: emergence of echinocandin resistance.
    Matsumoto E; Boyken L; Tendolkar S; McDanel J; Castanheira M; Pfaller M; Diekema D
    Diagn Microbiol Infect Dis; 2014 Jun; 79(2):205-8. PubMed ID: 24666704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular epidemiology of late recurrent candidaemia--a population-based study in Iceland.
    Asmundsdóttir LR; Erlendsdóttir H; Gísladóttir AL; Gottfredsson M
    Clin Microbiol Infect; 2012 Feb; 18(2):195-201. PubMed ID: 21733031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initial use of echinocandins does not negatively influence outcome in Candida parapsilosis bloodstream infection: a propensity score analysis.
    Fernández-Ruiz M; Aguado JM; Almirante B; Lora-Pablos D; Padilla B; Puig-Asensio M; Montejo M; García-Rodríguez J; Pemán J; Ruiz Pérez de Pipaón M; Cuenca-Estrella M; ; ;
    Clin Infect Dis; 2014 May; 58(10):1413-21. PubMed ID: 24642553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.